GHK-Cu punches above its molecular weight. At just three amino acids — glycine-histidine-lysine — chelated to copper(II), it is structurally among the simplest signalling peptides in the research catalogue. Yet the gene-expression footprint documented by Campbell et al. (2012) in BMC Genomics spans pathways governing collagen synthesis, antioxidant defence, anti-inflammatory signalling, and DNA repair — 32 of the 54 most dysregulated genes in Huntington's disease, regulated by a single copper tripeptide. For investigators sourcing peptides UAE to study tissue-remodelling, skin biology, or regenerative endpoints, GHK-Cu occupies a uniquely evidence-rich corner of the catalogue.
The practical challenge is not the molecule — it is the protocol architecture. Topical vehicles dominate the dermatology literature because GHK-Cu was first described in the skin-wound context. But a growing body of in-vivo work uses systemic (subcutaneous) delivery to assess whole-organism repair endpoints. These are different research tools. Choosing the wrong route for your experimental question means your results may not align with the published reference literature. This guide is for UAE research teams who want to get that decision right — and then source the right vial through a reliable ghk-cu in stock UAE supply channel.
Pickart & Margolina's 2018 review in Cosmetics remains the most comprehensive mechanistic overview of GHK-Cu in published research. They describe the tripeptide as a pleiotropic biological regulator: it activates genes for collagen, elastin, and glycosaminoglycan synthesis while simultaneously suppressing inflammatory cytokines (TNF-alpha, IL-6) and upregulating superoxide dismutase. In the skin-wound research context, the peptide operates through its copper-chelation capacity — copper is a cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin into functional extracellular matrix.
Pickart's 2008 summary in Advances in Wound Care established three cardinal observations from in-vivo wound-healing studies:
Then came the 2012 bioinformatics study. Campbell et al. used gene-chip microarray analysis to systematically map GHK-Cu's transcriptional effects across human cell cultures, identifying regulation of 54 genes in the Huntington's disease pathway alone — an unexpected finding that prompted a broader hypothesis: GHK-Cu may function as a systems-level reset signal, driving dysregulated gene networks toward a more youthful baseline. This is the mechanistic context that has expanded the GHK-Cu research agenda well beyond dermatology into aging biology, neuroprotection, and systemic repair.
The format question — injectable (subcutaneous) versus topical — is not aesthetic. It determines which literature your results will be comparable to, and which biological endpoints are even measurable in your model system.
| Parameter | Topical GHK-Cu | Subcutaneous GHK-Cu |
|---|---|---|
| Relevant literature | Pickart 2008 (wound healing); Pickart & Margolina 2018 (dermal collagen) | Campbell et al. 2012 (gene modulation); systemic repair studies |
| Primary endpoints | Dermal collagen density, wound closure rate, skin elasticity, local inflammation | Systemic gene expression, whole-tissue repair markers, antioxidant capacity |
| Bioavailability route | Transdermal penetration (variable, dependent on vehicle and skin barrier state) | Direct systemic absorption, bypasses first-pass and skin barrier |
| Concentration control | Difficult — tissue concentration depends on penetration efficiency | Precise — plasma concentration calculable from dose and volume |
| Vehicle considerations | Requires penetration enhancer (DMSO, liposomal, etc.) for meaningful tissue depth | Reconstituted in BAC or sterile water; standard SC injection technique |
| Typical research concentration | 0.1%–1% in topical vehicle | 0.5 mg–2 mg per administration in in-vivo wound models (Pickart 2008) |
| Stability post-preparation | Formulation-dependent; typically 30–90 days in sealed opaque vehicle | 14 days reconstituted at 2–8°C; indefinite lyophilized if cold-stored |
The summary decision logic: if your research question involves localized skin or wound endpoints and you need to compare against the Pickart cosmetic literature, topical is the appropriate format. If your question involves systemic gene-expression, whole-organ tissue response, or the DNA-repair and antioxidant pathways documented in Campbell et al. (2012), subcutaneous delivery provides the pharmacokinetic profile that matches those experimental conditions.
A common design in translational wound-healing research combines a systemic SC component (to prime circulating repair signals and raise systemic copper availability) with a topical component at the wound site (to saturate local receptor density). This dual-route design is not the default for beginners — it introduces confounding variables that require careful controls — but it mirrors how endogenous GHK-Cu is thought to function: the peptide is both a systemic signalling molecule released from damaged tissue into circulation and a locally concentrated ligand at the injury site. REVIVE LAB UAE's GHK-Cu 50mg and 100mg vials are formatted to support either route or both, depending on the investigator's experimental design.
REVIVE LAB UAE stocks GHK-Cu in two vial sizes: 50mg and 100mg. The choice between them is primarily a question of protocol duration and concentration targets. Both arrive lyophilized (freeze-dried powder) and require reconstitution with bacteriostatic water (BAC) or sterile water before use.
| Vial Size | BAC Water Added | Resulting Concentration | Volume per 1mg dose |
|---|---|---|---|
| GHK-Cu 50mg | 5 mL | 10 mg/mL | 0.10 mL (10 units on insulin syringe) |
| GHK-Cu 50mg | 10 mL | 5 mg/mL | 0.20 mL (20 units on insulin syringe) |
| GHK-Cu 100mg | 10 mL | 10 mg/mL | 0.10 mL (10 units on insulin syringe) |
| GHK-Cu 100mg | 20 mL | 5 mg/mL | 0.20 mL (20 units on insulin syringe) |
The 50mg vial is well-suited to shorter research windows — up to 6–8 weeks of daily administration at low concentrations — or to pilot protocols where the investigator wants to confirm assay sensitivity before committing to a larger supply. The 100mg vial is the economical choice for extended protocols, multi-arm studies, or topical preparation where higher total volume is needed. Both vials carry the same HPLC purity certificate and lot-specific COA standard applied across all REVIVE LAB UAE stock.
Dubai summer creates a specific logistical challenge for peptide research: ambient temperatures between May and September regularly exceed 42°C, meaning that even a 10-minute unprotected transit can compromise a vial's integrity. GHK-Cu, despite its small size, is sensitive to heat once reconstituted — copper chelation changes are accelerated at temperatures above 25°C, and oxidative degradation of the histidine residue is thermally facilitated.
| Form | Ideal Storage | Max Short Excursion | Do Not Exceed |
|---|---|---|---|
| Lyophilized (unopened) | 2–8°C fridge, dark | 25°C / 7 days | 30°C (degrades copper chelation) |
| Reconstituted (in solution) | 2–8°C fridge, dark | 20°C / 4 hours | 25°C (use within 4 hrs if unrefrigerated) |
| Transit (REVIVE LAB UAE dispatch) | Cold-chain insulated packaging | 2–8°C maintained 24–36 hrs | Validated for UAE summer dispatch |
REVIVE LAB UAE has built its dispatch protocol around UAE summer: every GHK-Cu shipment leaves in validated cold-chain insulation certified to hold 2–8°C through Dubai summer transit. Investigators in all seven emirates receive vials within the stability window — no heat compromise, no cold-chain excursions. This is a foundational part of what it means to buy ghk-cu UAE from a supplier that is actually operating here rather than shipping from offshore warehouses.
For UAE-based investigators, the sourcing decision is as important as the protocol decision. A peptide bought from an offshore vendor with no UAE cold-chain infrastructure may arrive compromised — particularly during summer. REVIVE LAB UAE is the Dubai-native peptides UAE supply solution: stock is held locally, dispatched cold, and verified by HPLC before it reaches any UAE research client.
| Emirate / Area | Delivery Window | Cash on Delivery | Cold Chain |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, JVC, DIFC, Downtown, Palm, Jumeirah) | Same-day, 4–8 hours | Yes | Yes |
| Abu Dhabi (Corniche, Yas, Saadiyat, Reem) | Next-day, 18–24 hours | Yes | Yes |
| Sharjah | Same-day / next-day, 8–18 hours | Yes | Yes |
| Ajman | Next-day, 18–24 hours | Yes | Yes |
| Ras Al Khaimah (RAK) | Next-day, 18–24 hours | Yes | Yes |
| Fujairah | Next-day, 24 hours | Yes | Yes |
| Umm Al Quwain (UAQ) | Next-day, 18–24 hours | Yes | Yes |
For investigators in Dubai Marina, Business Bay, JBR, JVC, DIFC, Palm Jumeirah, Downtown, Jumeirah, Emirates Hills or Arabian Ranches, ghk-cu same day Dubai dispatch is the standard, not a premium option. Orders placed before the daily cut-off reach the researcher the same afternoon or evening. Cash on delivery Dubai is accepted across all seven emirates as the default. Investigators who prefer digital payment can now also settle via USDT (TRC20) Binance Pay for a 5% pre-pay discount — a convenient option for researchers who routinely use USDT crypto pay Dubai for procurement. All shipments use plain, unbranded outer cartons.
To review available vial sizes and confirm current stock, see the GHK-Cu UAE product page — REVIVE LAB UAE updates availability daily.
Yes. REVIVE LAB UAE stocks GHK-Cu 50mg and 100mg vials in Dubai and dispatches same-day for orders placed before the daily cut-off. Investigators in Dubai Marina, JBR, Business Bay, JVC, DIFC, Palm Jumeirah, Downtown and Jumeirah typically receive HPLC-verified vials within 4–8 hours. Abu Dhabi, Sharjah, RAK, Fujairah and all other emirates receive next-day delivery within 24 hours. Cash on delivery is available across all seven emirates. USDT crypto payment (TRC20 via Binance Pay) is also accepted with a 5% pre-pay discount.
Both sizes are suited to subcutaneous research protocols. The 50mg vial is practical for shorter-duration windows, pilot studies, or lower-volume protocols. The 100mg vial offers better per-milligram value for extended research timelines, multi-arm experimental designs, or higher-volume reconstitutions. Reconstitution concentration is investigator-controlled regardless of vial size — both formats reconstitute cleanly with BAC water and deliver the same HPLC-verified purity and lot-COA documentation from REVIVE LAB UAE.
Topical GHK-Cu is the format documented in dermal collagen and skin-wound healing literature (Pickart & Margolina 2018; Pickart 2008), where localized tissue penetration is the delivery mechanism. Subcutaneous injection provides systemic exposure, making it the appropriate format for research comparing results against the gene-modulation literature (Campbell et al. 2012, BMC Genomics) or whole-tissue endpoint studies. Neither format constitutes a clinical or therapeutic recommendation — both are research tools for investigators working within defined experimental protocols. REVIVE LAB UAE supplies GHK-Cu for research purposes only.